PAK4 and breast carcinoma: In addition, in contrast to untransformed HMECs, ex vivo bulk tumor cells derived from breast cancer patients (patient-derived cells, PDCs) arrested proliferation upon PAK4–siRNA treatment (Supplementary Fig. 3j).